Comparative Pharmacology
Head-to-head clinical analysis: K TAB versus KLOTRIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K TAB versus KLOTRIX.
K-TAB vs KLOTRIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; restores intracellular and extracellular potassium levels, maintaining membrane potential and cellular function.
KLOTRIX is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The thiazide diuretic increases sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney.
Potassium chloride extended-release tablets, 20 mEq to 40 mEq orally per day in 2-4 divided doses with meals, titrated based on serum potassium levels.
Adults: 500-1000 mg orally every 6 hours; maximum 4000 mg/day.
None Documented
None Documented
7.5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl <10 mL/min)
Terminal half-life 12 hours; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min)
Renal (90% unchanged), fecal (10% as metabolites)
Renal 70% as unchanged drug, fecal 30% via biliary secretion
Category C
Category C
Potassium Supplement
Potassium Supplement